On April 5, 2024, the first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study) was reported in 2024 AACR.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.

On April 7, 2024, the latest clinical data of Cadonilimab (the PD-1/CTLA-4 bispecific antibody) plus chemo were reported in 2024 AACR.

Fresenius has declared through its subsidiary, Fresenius Kabi, the launch of Tyenne (tocilizumab-aazg) in the United States.

On April 5, 2024, the latest clinical trial of Atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk LA SCCHN were reported in 2024 AACR.

The "Berlin Patient" refers to Timothy Ray Brown, an American man who was known as the first person to be cured of HIV/AIDS.

On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.

Recurrence-free survival (RFS) is a clinical endpoint used in oncology to measure the effectiveness of cancer treatments.

April 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

EMA (European Medicines Agency) and HMA (Heads of Medicines Agencies) are two distinct organizations that play vital roles in the regulation of medicinal products, but their functions and scopes differ.

Arvinas has initiated a deal with Novartis that encompasses a worldwide licensing pact to advance and market their PROTAC® technology-based AR degrader ARV-766, aimed at prostate cancer therapies.

Information on ongoing clinical drug trials worldwide can be accessed through the several channels.